| Basics |
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs.
|
| IPO Date: |
April 12, 2006 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$318.53M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.24 | 2.38%
|
| Avg Daily Range (30 D): |
$0.13 | 2.56%
|
| Avg Daily Range (90 D): |
$0.10 | 2.08%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.57M |
| Avg Daily Volume (30 D): |
.84M |
| Avg Daily Volume (90 D): |
.57M |
| Trade Size |
| Avg Trade Size (Sh.): |
141 |
| Avg Trade Size (Sh.) (30 D): |
110 |
| Avg Trade Size (Sh.) (90 D): |
106 |
| Institutional Trades |
| Total Inst.Trades: |
3,109 |
| Avg Inst. Trade: |
$1.5M |
| Avg Inst. Trade (30 D): |
$.58M |
| Avg Inst. Trade (90 D): |
$1.08M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.56M |
| Avg Closing Trade (30 D): |
$.82M |
| Avg Closing Trade (90 D): |
$1.09M |
| Avg Closing Volume: |
121.04K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.38
|
$-.46
|
|
Diluted EPS
|
|
$-.38
|
$-.46
|
|
Revenue
|
$
|
$ 56.26M
|
$ 52.59M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -22.59M
|
$ -27.21M
|
|
Operating Income / Loss
|
$
|
$ -31.28M
|
$ -38.5M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -10.96M
|
$ -30.81M
|
|
PE Ratio
|
|
|
|
|
|
|
